Our Approach

Ardelyx develops:

  • Drugs that target proteins found in the gut whose activities affect the entire body
  • Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

What we do

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas



Reduce systemic uptake, minimize side effects.

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. Our molecules, whose systemic exposure is severely restricted, exploit natural mechanisms of nutrient transport and solute sensing occurring through intestinal epithelia. 

Program Indication PreclinPhase 1Phase 2Phase 3
RDX5791• Chronic Kidney Disease * * * * 
• End Stage Renal Disease * * * * 
• Heart Failure * * * * 
IBS-C, Constipation * * * * 
RDX002 Chronic Kidney Disease * * * * 
RDX009 Type 2 Diabetes * * * * 
RDX013 Hyperkalemia CKD * * * *